证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20150611 | --- | --- | --- | |-----------------------|--------------------------|----------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | | 尚阳投资张旭、泓德基金邬佳雁、泓德基金温永鹏、深圳承泽资 | | 员姓名 | 管钱振、中投证券李成等。 | | | 时间 | 2015 年 6 月 11 | 日 | | 地点 | 北京市海淀区丰慧中路 | 7 号新材料创业大厦 B 座 8 层会议室 | | | | | | 上市公司接待 人员姓名 | 董事会秘书：刘棣 | | | 投资者关系活 | 1 、董事长梁学贤先生 | 75 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20160623 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | | 北京时田丰投资管理有限公司 王禾 | | 员姓名 | | | | 时间 地点 | 2016 年 6 月 23 | 日 北京市大兴区生物医药产业基地庆丰西路 27 号 | | | | | | 上市公司接待 人员姓名 | 董事会秘书：刘棣 | | | 投资者关系活 | 1 | 、公司近期重组项目的标的广州龙之杰，能介绍一下该 | | 动主要内容介 | | | | 绍 | | 公司的情况吗？ ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20160823 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 富国基金 于洋 | | | 员姓名 | | | | | | | | 时间 地点 | 2016 年 8 月 23 | 日 北京市大兴区生物医药产业基地庆丰西路 27 号 | | | | | | 上市公司接待 人员姓名 | 董事会秘书：刘棣 | | | 投资者关系活 | 1 | 、目前公司重大资产重组项目的进展情况？ | | 动主要内容介 | | | | 绍 | 答：公司 | 2016 年 6 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20161117 | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 招商证券 刘旭 | | | 员姓名 | | | | 时间 地点 | 2016 年 11 月 17 | 日 北京市大兴区生物医药产业基地庆丰西路 27 号 | | | | | | 上市公司接待 人员姓名 | 董事会秘书：刘棣 | | | 投资者关系活 | 1 | 、对公司布局大健康领域收购广州龙之杰的项目，请介 | | 动主要内容介 | | | | 绍 | | 绍一下相关行业领域的情况和未 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20161102 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 华创证券 鲁佩 | | | 员姓名 | | | | 时间 | 2016 年 11 月 2 | 日 | | 地点 | | 北京市大兴区生物医药产业基地庆丰西路 27 号 | | | | | | 上市公司接待 人员姓名 | 董事会秘书：刘棣 | | | 投资者关系活 | 1 | 、目前公司重大资产重组项目的进展情况？ | | 动主要内容介 | | | | 绍 | 答：公司 | 2016 年 6 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20170111 | --- | --- | --- | |--------------|-------------------------|------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 国泰君安 马丁 | | | 员姓名 | | | | 时间 | 2017 年 1 月 11 | 日 | | 地点 | | 北京市大兴区生物医药产业基地庆丰西路 27 号 | | 上市公司接待 | | | | 人员姓名 | 董事会秘书：刘棣 | | | 投资者关系活 | 1 | 、近期公司重大资产重组项目重新恢复审查，请介绍一 | | 动主要内容介 | | | | 绍 | | 下此次收购标的博日鸿的相关行业领域的情况和未来发展前 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20171208 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 东兴证券 龙海敏 | | | 员姓名 | | | | 时间 | 2017 年 12 月 8 | 日 | | 地点 | | 北京市大兴区生物医药产业基地庆丰西路 27 号 | | 上市公司接待 人员姓名 | | 董事会秘书刘棣、投资部王瑜、证券部张金婷 | | 投资者关系活 | 1 | 、龙之杰的设备销售模式是怎样的？ | | 动主要内容介 | | | | 绍 | 答： | 龙之杰原有的销售 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20180511 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------| | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 民生证券 樊可 | | | 员姓名 | | | | 时间 | 2018 年 5 月 11 | 日 | | 地点 | | 北京市大兴区生物医药产业基地庆丰西路 27 号 | | 上市公司接待 人员姓名 | | 董事会秘书刘棣、投资部刘书成、证券部张金婷 | | 投资者关系活 | 1 | 、公司原有主营业务生物医药自动化控制系统业务未来 | | 动主要内容介 | | | | 绍 | 发展情况如何？ | | | ...

Group 1: Company Overview and Business Direction - The company focuses on expanding its business in the pharmaceutical industry through horizontal and vertical integration, aiming to broaden its service coverage [2] - The intelligent manufacturing segment primarily serves pharmaceutical and bioproduct manufacturing enterprises, with a strong emphasis on automation and control systems [2] - The company has developed a comprehensive range of services covering traditional and new business areas, including traditional Chinese medicine and chemical synthesis [3] Group 2: Intelligent Manufacturing and Software Solutions - The company has four major categories of software products, including Manufacturing Execution Systems (MES), Manufacturing Tracking Systems (MTS), Supervisory Control and Data Acquisition (SCADA), and Warehouse Management Systems (WMS) [3] - These software solutions are crucial for implementing Industry 4.0 and enhancing the company's overall solution capabilities [3] Group 3: Focus on Traditional Chinese Medicine - The company views the development of traditional Chinese medicine as a key growth area, actively promoting its business in this sector [3] - In 2018, the company acquired Jin'an Pharmaceutical Machinery to integrate its automation control advantages with Jin'an's products, creating a complete intelligent manufacturing solution for traditional Chinese medicine [3] Group 4: Rehabilitation Medical Equipment Sector - The company aims to enhance its product line in the rehabilitation medical equipment sector to meet clinical rehabilitation needs [4] - The focus is on self-developed products that improve existing offerings and develop new products based on clinical requirements [4] - The company is expanding its sales network to cover urban and grassroots medical institutions, enhancing its market presence [4] Group 5: Future Development and Market Potential - The company plans to leverage its acquisition of Guangzhou Shiri to develop a comprehensive rehabilitation solution for maternal and child health [4] - The rehabilitation industry has significant market potential due to the aging population and the implementation of the three-child policy, prompting the company to continue its growth strategy [4]

Financial Performance - The company's operating revenue for Q3 2022 was ¥248,379,985.95, representing a year-on-year increase of 25.55%[4] - The net profit attributable to shareholders for the same period was ¥23,623,661.37, a significant increase of 103.18% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses reached ¥23,086,224.91, up by 93.26% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.0900, an increase of 125.00% compared to the same period last year[4] - Total operating revenue for Q3 2022 was 613,666,273.60 CNY, an increase from 549,418,732.10 CNY in Q3 2021, representing a growth of approximately 11.7%[18] - Net profit attributable to shareholders of the parent company reached 75,244,757.38 CNY, up from 60,497,601.62 CNY in the same period last year, reflecting a growth of about 24.4%[19] - The total profit for Q3 2022 was 87,460,490.85 CNY, compared to 64,335,075.23 CNY in Q3 2021, which is an increase of approximately 36%[18] - Basic and diluted earnings per share for Q3 2022 were both 0.28 CNY, up from 0.22 CNY in the same quarter last year, representing a growth of 27.3%[19] - The company reported a net profit margin improvement, although specific figures were not disclosed in the provided content[17] - The total comprehensive income for Q3 2022 was 77,914,778.97 CNY, an increase from 60,975,159.42 CNY in Q3 2021, reflecting a growth of approximately 28%[19] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥3,050,264,533.76, reflecting a growth of 5.98% from the end of the previous year[4] - As of September 30, 2022, total assets amounted to CNY 3,050,264,533.76, up from CNY 2,878,023,044.88 at the beginning of the year, reflecting a growth of 6%[16] - Current assets totaled CNY 1,569,654,337.63, compared to CNY 1,513,140,178.44 at the start of the year, indicating an increase of 3.7%[14] - Total liabilities reached CNY 1,107,395,914.84, compared to CNY 1,013,577,622.40 at the beginning of the year, an increase of 9.3%[16] - The company's total equity attributable to shareholders was ¥1,918,430,226.15, up by 4.14% from the previous year-end[4] - The company's equity attributable to shareholders was CNY 1,918,430,226.15, up from CNY 1,842,222,326.69, indicating a growth of 4.1%[16] Cash Flow and Investments - Cash flow from operating activities showed a negative net amount of ¥75,952,785.61, indicating a decline of 413.90% year-to-date[4] - The company reported a net cash flow from operating activities of -75,952,785.61 CNY, a decline from a positive cash flow of 24,196,550.35 CNY in Q3 2021[20] - The company's cash and cash equivalents decreased to CNY 141,844,424.53 from CNY 256,356,705.42, representing a decline of 44.5%[14] - Cash and cash equivalents at the end of the period were 117,495,909.16 CNY, down from 167,650,268.52 CNY at the end of Q3 2021, indicating a decrease of about 30%[21] - The company experienced a decrease in net cash flow from investing activities, reporting -73,095,416.98 CNY compared to -93,371,326.00 CNY in Q3 2021[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,539, with the top ten shareholders holding significant stakes[10] - The company's short-term borrowings increased by 38.27% compared to the beginning of the year, attributed to an increase in bank short-term loans[7] Research and Development - Research and development expenses increased to 45,131,474.61 CNY, compared to 35,457,404.13 CNY in Q3 2021, marking a rise of approximately 27.3%[18] Future Strategies - Future strategies include potential market expansion and new product development, although detailed plans were not specified in the content[17]